A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation is a phase 3 interventional study registered as NCT07668752, led by Genfleet Therapeutics (Shanghai), and recruiting on the registry. Official title: A Phase III, Randomised, Open-Label, Multicenter Study to Evaluate GFH375 Versus Docetaxel in Participants With Locally Advanced and Unresectable or Metastatic Non-Small Cell Lung Cancer With KRAS G12D Mutation Failed Prior Standard Therapy. Planned enrolment is 300 participants (estimated). The study started in 2026-07-27 and primary completion is expected in 2030-06-30. No results have been posted on ClinicalTrials.gov.